Jade Biosciences, Inc. Professional Fees
Jade Biosciences, Inc. (JBIO) reported Professional Fees of $11.48 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProfessionalFees · last filed 2025-03-27
- Jade Biosciences, Inc. professional fees for fiscal 2024 was $11.48M, a 82.57% increase from fiscal 2023.
- Jade Biosciences, Inc. professional fees for fiscal 2023 was $6.29M.
| Period end | Professional Fees 12 month |
|---|---|
| 2024-12-31 | $11.48M 10-K · filed 2025-03-27 |
| 2023-12-31 | $6.29M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |